Exploring Big Pharma’s Direction in Neurodegenerative Disease

Time: 9:00 am
day: Day One


  • Analyzing current neurodegenerative drug development bottlenecks and strategizing how to progress beyond them: Spotlight on modelling, biomarkers and investment approaches
  • Exploring transformative new platforms on the horizon for Alzheimer’s, ALS, Parkinson’s, Huntington’s and more
  • Learning how to effectively incorporate novel research into your drug development approach to maximize success commercially and in the clinic